Natco Pharma supports Columbia University trials to CQ tablets to prevent COVID19 infection

The trial aim to determine the effectiveness of the Chloroquine phosphate in preventing COVID19 infection in healthcare workers


1 min read
Natco Pharma supports Columbia University trials to CQ tablets to prevent COVID19 infection

Natco Pharma Limited on Friday said it will support a clinical trial conducted by Columbia University, New York to determine the effectiveness of CQ in treatment of Coronavirus.

The Company through its marketing partner in the United States, Rising Pharmaceuticals will donate CQ tablets to support the phase 2 of a clinical trial at Columbia University, Natco Pharma mentioned in a regulatory filing.

The trial aim to determine the effectiveness of the Chloroquine phosphate in preventing COVID19 infection in healthcare workers with moderate to high risk of exposure to the Coronavirus, it said.

Recently, NATCO has donated Chloroquine Phosphate tablets to a global clinical trial conducted by the CROWN Collaborative at the Washington University School of Medicine in St. Louis.

The company said scientists at Columbia University are conducting this critical study to assess Chloroquine phosphate as phosphylaxis against Coronavirus in healthcare workers. The Phase 2 trial of CQ will enrol 350 volunteers who work in direct patient care roles at Columbia University Irving Medical Center and who have contact with patients, who may have infected with the COVID19 infection.

Also read World carbon pollution falls 17% during pandemic: Study

NATCO has been supplying Chloroquine Phosphate tablets, a USFDA approved drug, through it's marketing partner to the United States since 2011. Columbia University is renowned all over the world for its expertise in conducting well designed clinical trials and NATCO is glad to work with them on this path-breaking trial, the company mentioned.

GO TOP